entertainment -WSS

entertainment

author：hotspot 2025-09-30 16:29:38 - browse：9243

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Reports of telehealth's death have been greatly exaggerated

leisure time

WSS

HPV vaccine, cervical cancer study delivers historic results

Scrutiny of post

ASCO eve: Let’s set the table for this year's meeting

Future doctors need a strong humanities education

H5N1 bird flu outbreak: Second human case reported, in Michigan

CVS is on a mission to consolidate health care. Will it work?

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

HPV vaccine, cervical cancer study delivers historic results

At least 13 dead in Texas as scorching temps continue

Addressing health care workers' trauma can help fight burnout

Drug repurposing or repositioning? The language matters

Mass General, Mayo Clinic look to monetize custom

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Questions and answers about ramping up H5N1 bird flu vaccine

After affirmative action ruling, medical educators look to 'holistic review'

CVS is on a mission to consolidate health care. Will it work?

Wikipedia

Microsoft launches AI tool for clinical documentation through Epic

A pediatrician calls for Congress to pass the child tax credit deal

Investigation reveals sickle cell patients pressured into sterilizations

FDA endorses new sterilization method for medical devices

Cue Health, Covid

Pumping milk in bathrooms at health conferences is common

leisure time

focus

focus

explore